STAHIST AD- chlorcyclizine hydrochloride and pseudoephedrine hydrochloride tablet 
Magna Pharmaceuticals, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Stahist AD

Drug Facts

Active Ingredients
(in each immediate-release tablet)
Purpose
Chlorcyclizine HCl 25 mgAntihistamine
Pseudoephedrine HCl 60 mgNasal Decongestant

Uses

temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies:

Warnings

Do not exceed recommended dosage.

Do not use this product

  • If you are taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for two weeks after stopping the MAOI drug. If you do not know if your prescription drug contains MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

  • a breathing problem such as emphysema or chronic bronchitis
  • glaucoma
  • heart disease
  • high blood pressure
  • thyroid disease
  • diabetes melitus
  • difficulty in urination due to enlargement of the prostate gland

Ask a doctor before use if you are taking sedatives or tranquilizers

When using this product

  • excitability may occur, especially in children
  • may cause drowsiness
  • alcohol, sedatives and tranquilizers may increase drowsiness effect
  • avoid alcoholic beverages
  • use caution when driving a motor vehicle or operating machinery

Stop use and ask a doctor if

  • nervousness, dizziness or sleeplessness occur
  • symptoms do not improve within 7 days or are accompanied by fever
  • new symptoms occur

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children.

In case of accidental overdose, seek professional help or contact a Poison Control Center immediately.

Directions

Do not exceed recommended dosage.

Adults and children 12 years of age and over:1 tablet by mouth every 6-8 hours, not to exceed 3 tablets in 24 hours, or as directed by a doctor
Children 6 to under 12 years of age:½ tablet by mouth every 6-8 hours, not to exceed 1½ tablets in 24 hours, or as directed by a doctor
Children under 6 years of ageConsult a doctor

Inactive ingredients

Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate

Questions or Comments?

Call 1-888-206-5525 • www.magnaweb.com

Rev. 10/11

PRINCIPAL DISPLAY PANEL - 25 mg/60 mg Tablet Carton

NDC 58407-625-30

Antihistamine • Nasal Decongestant

Stahist AD

Each tablet contains:
Chlorcyclizine HCl 25 mg
Pseudoephedrine HCl 60 mg

MAGNA
Pharmaceuticals, Inc.
Louisville, KY 40299

30 Tablets

PRINCIPAL DISPLAY PANEL - 25 mg/60 mg Tablet Carton

STAHIST AD 
chlorcyclizine hydrochloride and pseudoephedrine hydrochloride tablet
Product Information
Product TypeHUMAN OTC DRUG LABELItem Code (Source)NDC:58407-625
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CHLORCYCLIZINE HYDROCHLORIDE (CHLORCYCLIZINE) CHLORCYCLIZINE HYDROCHLORIDE25 mg
PSEUDOEPHEDRINE HYDROCHLORIDE (PSEUDOEPHEDRINE) PSEUDOEPHEDRINE HYDROCHLORIDE60 mg
Inactive Ingredients
Ingredient NameStrength
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
Product Characteristics
ColorWHITEScore2 pieces
ShapeOVALSize16mm
FlavorImprint Code M625
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:58407-625-301 in 1 BOX
130 in 1 BOTTLE
2NDC:58407-625-066 in 1 BOX
2NDC:58407-625-011 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC MONOGRAPH FINALpart34112/20/2011
Labeler - Magna Pharmaceuticals, Inc. (620988360)

Revised: 12/2011
Document Id: 88837b25-44c9-47ec-9e8b-a26ee3cb2419
Set id: ccedbc38-2479-4c35-9f86-a9f29bcfab3f
Version: 1
Effective Time: 20111222
 
Magna Pharmaceuticals, Inc.